FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Medscape1d
FDA Okays New Rapid-Acting Biosimilar Insulin for Diabetes
The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...
조선일보1d
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage
FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.